ALXO News and Press, ALX Oncology Holdings Inc. From 11/13/23

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results ...

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in three...

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the closing of it...

2023-10-09 10:00:00 ET More on Health Care Select Sector SPDR Citi turns cautious on pharmaceuticals and biotech BofA Securities: Which small cap non-earner stocks to avoid For further details see: Bioline Rx, Clever Leaves among healthcare movers

2023-10-09 00:38:06 ET Summary ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastroesophageal junction cancer. Final results from the ASPEN-06 study are expected to be released in Q2 2024, potentially leadi...

2023-10-06 17:01:32 ET More on ALX Oncology ALX Oncology Holdings: Gilead News Creates A New Risk ALX Oncology announces pricing of its public offering ALX Oncology announces proposed public offering Seeking Alpha’s Quant Rating on ALX Oncology ...

2023-10-05 08:25:39 ET More on ALX Oncology ALX Oncology Holdings: Gilead News Creates A New Risk ALX Oncology announces proposed public offering Seeking Alpha’s Quant Rating on ALX Oncology For further details see: ALX Oncology announces pricing o...

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the pricing of it...

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that it has comme...

2023-10-04 09:59:33 ET More on Health Care Select Sector SPDR September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Citi turns cautious on pharmaceuticals and biotech BofA Securities:...